Skip to main content

Table 1 Details of field samples used to generate six Fasciola hepatica clonal isolates

From: Clonal amplification of Fasciola hepatica in Galba truncatula: within and between isolate variation of triclabendazole-susceptible and -resistant clones

Clonal isolate Origin of F. hepatica eggs Geographical location of farm History of TCBZ exposure
FhLivR1 Purged from adult parasites recovered at PM (AHVLA) North West England Frequent use of TCBZ, treated with TCBZ 28 days prior to PM and 2 days prior to PM. Sheep died 2 days post-treatment
FhLivR2 Isolated from faecal sample taken 21 days post-TCBZ treatment South Wales Population of F. hepatica showing 98.2% reduction based on FECRTa
FhLivR3 Purged from adult parasites recovered at PM (AHVLA) North West England (not same farm as R1) History of TCBZ treatment failure on farm, last exposed to TCBZ 4 months prior to PM
FhLivS1 Shrewsbury laboratory isolate, commercially available TCBZ susceptible population (Ridgeway Research Ltd, UK) Isolated 2006 from West England Population of F. hepatica showing TCBZ efficacyb of 97% in sheep (n = 9), Ridgeway Research Ltd (pers. comm.)
FhLivS2 Isolated from faecal samples from organic sheep farm North West England (not same farm as R1 or R3) None
FhLivS3 Isolated from faecal samples from organic sheep farm South West England Population of F. hepatica showing TCBZ efficacyb of 97.2% in sheep (n = 12, data not shown)
  1. aTCBZ-S based on criteria for faecal egg count reduction test (FECRT) [45]
  2. bTCBZ % efficacy defined based on critical test performed at 10 days after treatment and using the following calculation: % efficacy = (mean of F. hepatica in control group – mean of F. hepatica in treated group/ mean of F. hepatica in control group) × 100 [46]
  3. Abbreviations: PM post-mortem, AHVLA/APHA Animal Health Veterinary Laboratory Agency/Animal and Plant Health Agency, TCBZ triclabendazole